Literature DB >> 14751082

Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14751082     DOI： 10.1007/s11912-004-0014-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  9 in total

1.  Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol.

Authors:  L H Einhorn; S D Williams; P J Loehrer; R Birch; R Drasga; G Omura; F A Greco
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

2.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  Jeffrey Bell; Mark F Brady; Robert C Young; Janice Lage; Joan L Walker; Katherine Y Look; G Scott Rose; Nick M Spirtos
Journal:  Gynecol Oncol       Date:  2006-07-24       Impact factor: 5.482

3.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

4.  Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.

Authors:  D R Miller; S L Leikin; V C Albo; H Sather; G D Hammond
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

5.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

6.  International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

Authors:  J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Constantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

7.  Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.

Authors:  J Baptist Trimbos; Ignace Vergote; Giorgio Bolis; Jan B Vermorken; Constantino Mangioni; Caterina Madronal; Massimo Franchi; Saverio Tateo; Gerardo Zanetta; Giovanna Scarfone; Livia Giurgea; Petra Timmers; Corneel Coens; Sergio Pecorelli
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

8.  International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

Authors:  Nicoletta Colombo; David Guthrie; Stefania Chiari; Mahesh Parmar; Wendi Qian; Ann Marie Swart; Valter Torri; Christopher Williams; Andrea Lissoni; Cristina Bonazzi
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

9.  Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

Authors:  Pierre Fumoleau; Pierre Kerbrat; Pascale Romestaing; Pierre Fargeot; Alain Brémond; Moïse Namer; Simon Schraub; Marie-Jo Goudier; Jeanne Mihura; Alain Monnier; Pierre Clavère; Daniel Serin; Philippe Seffert; Christiane Pourny; Thomas Facchini; Jean-Philippe Jacquin; Jean-François Sztermer; Jean Datchary; René Ramos; Elisabeth Luporsi
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.